Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CCNK | O75909 | 1/20 | 0.37 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30527606 | 1.00 | GPR119 (0.44) | GPR119KDM4EIDO1HPGDSUSP30 | |
| SCHEMBL25262540 | 0.85 | GPR119 (0.54) | GPR119KDM4EIDO1CYP2C9 | |
| SCHEMBL30527746 | 0.85 | GPR119 (0.54) | GPR119KDM4EIDO1CYP2C9 | |
| SCHEMBL25305154 | 0.83 | GPR119 (0.49) | GPR119KDM4EIDO1CYP2C9 | |
| SCHEMBL31250355 | 0.83 | GPR119 (0.49) | GPR119KDM4EIDO1CYP2C9 | |
| SCHEMBL25307728 | 0.82 | GPR119 (0.46) | GPR119KDM4EIDO1CYP2C9 | |
| SCHEMBL31066403 | 0.82 | GPR119 (0.48) | GPR119KDM4EIDO1CYP2C9 | |
| SCHEMBL25888794 | 0.81 | GPR119 (0.62) | GPR119KDM4EIDO1USP30 | |
| SCHEMBL25306751 | 0.81 | GPR119 (0.52) | GPR119KDM4EIDO1USP30 | |
| SCHEMBL31655197 | 0.80 | GPR119 (0.49) | GPR119KDM4EIDO1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4463459-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | GPR119 399/4885KDM4E 1488/4885IDO1 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.